GGrantIndex
← Leaderboards

Judith B Grinspan

University Of Pennsylvania

$7,508,303
Attributed
$13,793,106
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY201225
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,793,106 · 5

By mechanism

R01$12,848,929 · 3
R21$944,177 · 2

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Oligodendroglia

Research focus

OligodendrogliaWhite MatterMyelinMyelinationCognitiveBehavioralHiv InfectionsBrainAntiretroviral TherapyGenesIn VitroPharmaceutical PreparationsAdultIn VivoMyelin ProteinsMyelin SheathNucleosidesHiv-Associated Neurocognitive DisorderProtein ExpressionRemyelinationPathologicFunctional DisorderPathway InteractionsReverse Transcriptase Inhibitors

Grant awards (26)

Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$747,327
R01 · FY2025 · MH
Effects of HIV and ART on myelination in the adolescent$736,887
R01 · FY2025 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$870,237
R01 · FY2024 · MH
Effects of HIV and ART on myelination in the adolescent$743,474
R01 · FY2024 · MH
Effects of HIV and ART on myelination in the adolescent$749,967
R01 · FY2023 · MH
Effects of HIV and ART on myelination in the adolescent$757,832
R01 · FY2022 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$681,635
R01 · FY2022 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$110,367
R01 · FY2022 · MH
Effects of HIV and ART on myelination in the adolescent$867,647
R01 · FY2021 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$681,323
R01 · FY2021 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$681,019
R01 · FY2020 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$422,500
R01 · FY2020 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$680,724
R01 · FY2019 · MH
Modulation of myelination by IL-4 following intrauterine growth restriction$215,000
R21 · FY2019 · NS · contact PI
Effect of HIV and ART therapy on developmental myelination$205,294
R21 · FY2019 · MH · contact PI
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$710,938
R01 · FY2018 · MH
Effect of HIV and ART therapy on developmental myelination$265,883
R21 · FY2018 · MH · contact PI
Modulation of myelination by IL-4 following intrauterine growth restriction$258,000
R21 · FY2018 · NS · contact PI
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$532,571
R01 · FY2016 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$532,571
R01 · FY2015 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$532,571
R01 · FY2014 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$511,268
R01 · FY2013 · MH
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorder$547,571
R01 · FY2012 · MH
Regulation of oligodendrocyte differentiation by BMP$242,250
R01 · FY2004 · NS
Regulation of oligodendrocyte differentiation by BMP$242,250
R01 · FY2003 · NS
Regulation of oligodendrocyte differentiation by BMP$266,000
R01 · FY2002 · NS